MedPath

Keytruda fails lung and skin cancer trials, limiting further expansion - BioPharma Dive

Merck's Keytruda failed in two clinical trials for early-stage lung and skin cancer, leading to early termination. This setback impacts Merck's expansion plans for Keytruda before its patent expires in 2028, despite the drug being one of the best-selling pharmaceuticals with $14 billion in sales in the first half of 2024.


Reference News

Keytruda fails lung and skin cancer trials, limiting further expansion - BioPharma Dive

Merck's Keytruda failed in two clinical trials for early-stage lung and skin cancer, leading to early termination. This setback impacts Merck's expansion plans for Keytruda before its patent expires in 2028, despite the drug being one of the best-selling pharmaceuticals with $14 billion in sales in the first half of 2024.

© Copyright 2025. All Rights Reserved by MedPath